OpenAI Launches GPT-Rosalind for Life Sciences
Key Questions
What is GPT-Rosalind and its purpose?
OpenAI launched GPT-Rosalind for life sciences, focusing on genomics, proteins, and drug discovery. It partners with Amgen and Moderna to slash 10-15 year timelines.
What AI investments are happening in biotech?
Boehringer Ingelheim opened a £150M AI center in London, and Penn invested $18M in an RNA Foundry. These support domain-specific biotech acceleration.
How is AI impacting drug testing and organoids?
AI organoid platforms enable automation, potentially phasing out FDA animal testing. They transform research alongside precision therapeutics paths.
GPT-Rosalind for genomics/proteins/drug discovery partners Amgen/Moderna slashing 10-15yr timelines; Boehringer £150M AI center London, Penn $18M RNA Foundry, organoid AI platforms FDA animal phase-out; domain-specific biotech acceleration.
Sources (2)
Updated Apr 20, 2026